methylen trial sight well-plac
cosmo well financ withstand relat disrupt includ
launch aemcolo gi geniu eleview lower revenu importantli
final protocol confirmatori methylen blue mmx phase trial
submit could allow studi start continu believ
could signific long-term valu cosmo multipl equiti stake reflect
current price henc buy pt
second methylen blue phase could start cosmo submit
final clinic trial protocol fda second confirmatori us phase trial
methylen blue mb mmx respons expect within day albeit
could delay pandem fda approv receiv
assum clinic trial oper normalis trial could start
whilst understand trial differ endpoint first trial
like focus non-polypoid adenoma detect rate adr perhap enabl
smaller faster trial despit cosmo continu target data month
initi timelin remain conserv assum month
trial complet trial set commenc earli
shift data us launch
continu forecast ww peak sale probabl in-lin
partner strategi assum us deal mb mmx rather cosmo
commercialis alon lower npv
could disrupt multipl product launch seem like
aemcolo sale travel diarrhoea partner redhil launch
decemb could stall year given relat travel restrict addit
colonoscopi like disrupt impact gi geniu launch europ
on-going us trial secur fda approv eleview sale
also like interrupt byfavo juli pdufa decis date cosmo
confid impact manufactur inspect
alreadi complet
shift equity-for-product deal make strateg sens cosmo recent complet
two deal sublicens ultra-short act sed byfavo remimazolam out-
licens us aemcolo right cosmo take equiti stake partner
compani byfavo approv first sale cosmo receiv
partner cash payabl paion cash/shar cosmo
grant loan barhemsi approv feb
byfavo approv cosmo could also receiv commerci mileston
exceed cosmo owe paion june deal plu royalti
match owe paion aemcolo cosmo receiv up-front
redhil invest acquir total
stake rdhl owe futur mileston assum
relat potenti futur ibs-d develop other sales-rel plu
royalti sale includ product suppli
cosmo exclud except gains/loss
sale invest demerg entiti
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
cosmo exclud except gains/loss sale invest demerg entiti
cosmo aim leverag mmx colon drug deliveri
technolog maximis valu gi product
us market equity-for-product deal
demerg asset new entiti crystallis valu
lialda uceri ulcer coliti colonoscopi
rifafalk rifamycin sv mmx plu pipelin
price base npv
posit poc data antibiot aemcolo/rifafalk
ibs-d gi indic could
gain eu approv methylen blue mmx
faster us trial anticip could
cassiopea share could rise toward upsid
scenario boost valu cosmo invest
period catalyst togeth
number smaller event could boost npv
deriv price
prolong regulatori delay methylen blue mmx
discontinu could remov
byfavo regulatori concern delay approv
procedur sedat could remov
toward
downsid scenario lower valu cosmo
invest
period setback
could lower npv deriv price
cosmo commit return profit
manag past
return excess cash sharehold anticip
manag execut equity-for-product right
deal and/or establish newco maximis
valu us commerci opportun tax effici
aemcolo/rifafalk phase ii data ibs-d
start second mb mmx phase trial
complet launch shortli thereaft
byfavo/remimazolam us approv around juli
aemcolo latin america asia
pleas see import disclosur inform page report
retain buy price cut
cosmo leverag mmx colon drug deliveri technolog aim maximis
commerci opportun gi product lucr us market primarili via
equity-for-product out-licens deal us gastrointestin gi restructur
mb mmx setback aemcolo byfavo remimazolam out-
licens partner commerci right current retain mb mmx sinc
incept manag maintain effici cost structur typic out-
licens late-stag drug anticip remain strategi partner
medtron commercialis eleview aid remov polyps/adenoma
artifici intellig modul gi geniu aim improv detect rate
colonoscopi npv sum-of-the-part valuat continu suggest current
share price undervalu potenti lucr us gi commerci opportun
upsid success new launch potenti increment partnership deal
retain belief mb mmx potenti
sale forecast us
valuat per share probabl commerci success
news flow us phase initi eu approv around licens
deal commercialis
methylen blue mmx novel diagnost assist colonoscopi procedur despit
need addit phase trial us scope design
discuss still regard mb mmx valuabl asset cosmo pipelin
potenti signific commerci opportun understand second trial
may differ endpoint first trial like focus non-polypoid adenoma
detect rate adr perhap enabl smaller faster trial
first mb mmx phase conduct year first patient
enrol februari headlin result disclos novemb follow
confirm second phase trial need appeal process
assum second phase initi experi enabl rapid
complet could allow mb mmx re-fil potenti
approv european regulatori file submit februari
remain impress simplic product use mmx conveni appli
well-known dye methylen blue colon chromoendoscopi endoscopi use
intravit dye topic appli mucos surfac methylen blue select
absorb normal colon columnar cell dys-/neo-plast cell make ideal
assist diagnosi colon cancer premalign polyp dye
use year food addit somewhat limit use chromoendoscopi
manual applic prior procedur latter costli process intens
potenti messi clinician henc would expect conveni tablet form
mb mmx rapidli adopt
phase confirm mb mmx could reduc risk colon cancer
mb mmx met primari endpoint phase trial substanti improv
number subject least one histolog proven adenoma/carcinoma versu
high-definit white-light hdwl colonoscopi current gold standard care
vs baselin detect rate higher
assum like reflect expert site use trial nevertheless mb mmx
correctli identifi patient benefit typic
pleas see import disclosur inform page report
detect rate around ordinari clinic practic benefit mb mmx
could even profound broader endoscopi commun
importantli key secondari endpoint fals posit rate lower mb
mmx vs demonstr subject lesion requir
excis correctli identifi vs hdwl furthermor common cohort
requir excis patient detect rate vs
clinic relev view improv detect
non-polypoid flat lesion explain much benefit afford mb mmx
vs subject flag
phase trial enrol patient polyp hospit north america
europ number site increas acceler patient enrol
given rel oner protocol physician follow data integr
subject randomis mb mmx versu hdwl vs mb mmx
patient took standard bowel prepar
exhibit detail phase result confirm compel benefit mb mmx
jefferi research adapt cosmo present novemb
studi demonstr endoscopist adr significantli associ
risk interv colorect cancer screen colonscopi nejm bretagn et
al may adr vari substanti endoscopist rate europ report
increas adr associ decreas
risk cancer lower risk fatal interv nejm corley et al april
risk interv cancer subject assess endoscopist lowest
quintil adr twice highest quintil adr improv
least one quintil associ decreas incid interv cancer
lower risk death interv cancer kaminski ddw given
close correl risk cancer adr believ patient physician
payer motiv adopt mb mmx clinician feedback suggest mb
mmx highli like adopt colonoscopi guidelin heard
flaw concern surround product
us payer must cover screen colonoscopi out-of-pocket cost basic
procedur howev drug mb mmx would bill separ part
medicar understand patient typic spend out-of-pocket cover some/
cost conveni brand bowel prep solut may also
model mb mmx patients/physician motiv higher detect rate
pleas see import disclosur inform page report
mb mmxhdwlrrrp valuen full analysi set first time screen surveil colonoscopi year sinc surveil colonoscopi year sinc per protocol histolog proven adenoma/carcinoma adr adr per posit subject requir subject requir histolog proven non-polypoid diminut equiti research
believ impress phase data compel us payer grant mb
mmx favour formulari tier low co-pay may biggest factor
determin us peak sale potenti
estim us list price around averag revenu per procedur
premium price brand bowel prep outsid
us assum lower averag revenu per procedur current understand
endoscopi like utilis dye perhap rise expert
centr assum mb mmx boost adopt chromocolonscopi
us ex-u respect procedur per annum
adopt rate could modest overal number colonoscopi like
conserv particularli given nation programm rais awar primari
screen
exhibit chang forecast
pleas see import disclosur inform page report
price cut
price base npv sum-of-the-part valuat continu
offer potenti upsid current share price includ contribut
phase cancer asset given stage develop
exhibit cosmo sourc upsid potenti downsid risk
pleas see import disclosur inform page report
peakvalueadj valuechfindicationsal mn eurmn prob eurmn per sharelialda/mezavantulc rifamycin sv mmx infecti diarrhoea blue mmxchromoendoscopi solut polyp geniu artifici intellig cassiopea paion redhil dilut dilut sharedownsidep shareaemcolo/relafalk studi ibs-d sibo heposit blue mmx regulatori decisionseu approv expedit us phase us investmentachiev price target scenario investmentupsid scenario us fda decisionu exhibit cosmo catalyst
pleas see import disclosur inform page report
